[CAS NO. 1311423-89-8] YF-2
PRODUCTS SPECIFICATIONS [1311423-89-8]
DESCRIPTION [1311423-89-8]
Overview
| MDL | MFCD22665763 |
|---|---|
| Molecular Weight | 430.85 |
| Molecular Formula | C20H22ClF3N2O3 |
| SMILES | O=C(NC1=CC=C(Cl)C(C(F)(F)F)=C1)C2=C(OCC)C=CC=C2OCCN(C)C |
1 Publications Citing Use of MCE
Summary
YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC 50 s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC . Anti-cancer and anti-Alzheimer's disease [1] .
IC50 & Target
|
GCN5 49.31 μM (EC 50 ) |
In Vitro
YF-2 (0.03, 0.1, 0.25, 0.5, 1, 2.5, 5, 15, 40 and 80 μM, 72 hours) inhibits the preliferation of U251, CCRF-CEM, Hs578T, NCI-ADR-RES cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
YF-2 (20 mg/kg, 2 hours befor electric shock or 5 mg/kg, 30 min before the electric shock, i.p.) rescues the defect in contextual memory in mice, and shows no effect on contextual memory alone at 20 mg/kg in mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 125 mg/mL ( 290.12 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3210 mL | 11.6050 mL | 23.2099 mL |
| 5 mM | 0.4642 mL | 2.3210 mL | 4.6420 mL |
| 10 mM | 0.2321 mL | 1.1605 mL | 2.3210 mL |
References